New Blue Health utilizes a structured methodology to evaluate and grade clinical evidence. Our goal is to provide patients with a clear understanding of the "strength" of the science behind various longevity and metabolic pathways. We do not "cherry-pick" data to support a specific outcome; instead, we present the full landscape of current research, including where data may be conflicting or limited.
The Evidence Hierarchy
1. Level 1: Regulatory Gold Standard - FDA-approved drug labels and large-scale Phase III Randomized Controlled Trials (RCTs). This represents the highest level of clinical certainty.
2. Level 2: Peer-Reviewed Clinical Data - Smaller RCTs, longitudinal observational studies, and meta-analyses published in reputable medical journals.
3. Level 3: Mechanistic & Pre-clinical Research - In-vitro or animal model studies that describe a molecule's potential mechanism of action but have limited or no human validation.
Transparency Commitment
Evidence quality varies significantly by molecule. For instance, molecules like Semaglutide have an extensive body of Level 1 evidence, while newer peptides may rely more on Level 2 or Level 3 data. We explicitly state uncertainty where it exists. If a molecule's primary benefit is based on mechanistic theory rather than human outcome data, we prioritize that distinction for our patients.
See our Sources.